ABSTRACT
Boosting the production of recombinant therapeutic antibodies is crucial in both academic and industry settings. In this work, we investigated the usage of varying signal peptides by antibody V-genes and their roles in recombinant transient production, systematically comparing myeloma and the native signal peptides of both heavy and light chains in 168 antibody permutation variants. We found that amino acids count and types (essential or non-essential) were important factors in a logistic regression equation model for predicting transient co-transfection protein production rates. Deeper analysis revealed that the culture media were often incomplete and that the supplementation of essential amino acids can improve the recombinant protein yield. While these findings are derived from transient HEK293 expression, they also provide insights to the usage of the large repertoire of antibody signal peptides, where by varying the number of specific amino acids in the signal peptides attached to the variable regions, bottlenecks in amino acid availability can be mitigated.
Subject(s)
Amino Acids/metabolism , Antibodies, Monoclonal, Humanized/biosynthesis , Antineoplastic Agents, Immunological/metabolism , Biotechnology , Immunoglobulin E/biosynthesis , Immunoglobulin Variable Region , Protein Engineering , Protein Sorting Signals , Trastuzumab/biosynthesis , Antibodies, Monoclonal, Humanized/genetics , Culture Media/metabolism , HEK293 Cells , Humans , Immunoglobulin E/genetics , Immunoglobulin Variable Region/genetics , Multiple Myeloma/genetics , Multiple Myeloma/immunology , Protein Sorting Signals/genetics , Recombinant Proteins/biosynthesis , Trastuzumab/genetics , WorkflowABSTRACT
Antibody drugs have been used to treat many diseases, and to date, this has been the most rapidly growing drug class. However, the lack of suitable methods for real-time and high-throughput monitoring of antibody production and quality control has been a hindrance to the further advancement of antibody drugs or biosimilars. Therefore, we herein report a versatile tool for one-step fluorescence monitoring of antibody production by using aptamer probes selected through the in vitro SELEX method. In this case, DNA aptamers were selected against the humanized IgG1 antibody drug trastuzumab with high specificity and affinity with a Kd value of aptamer CH1S-3 of 10.3 nM. More importantly, the obtained aptamers were able to distinguish native from heat-treated, whereas antibodies failed this test. On the basis of the advantages of rapid detection for aptamers, we designed aptamer molecular beacons for direct and sensitive detection of trastuzumab in complex samples. Unlike traditional antibody-based ELISA, the signal was observed directly upon interaction with the target without the need for time-consuming binding and multiple washing steps. To further highlight biomedical applications, the use of aptamers as potential tools for quality control and traceless purification of antibody drugs was also demonstrated. Thus, aptamers are shown to be promising alternatives for antibody production monitoring, quality control, and purification, providing technical support to accelerate antibody drug development.
Subject(s)
Aptamers, Nucleotide/chemistry , SELEX Aptamer Technique , Trastuzumab/analysis , Antibody Formation , Fluorescence , Quality Control , Trastuzumab/biosynthesisABSTRACT
Increased commercial demand for monoclonal antibodies (mAbs) has resulted in the urgent need to establish efficient production systems. We previously developed a transgenic chicken bioreactor system that effectively produced human cytokines in egg whites using genome-edited transgenic chickens. Here, we describe the application of this system to mAb production. The genes encoding the heavy and light chains of humanized anti-HER2 mAb, linked by a 2A peptide sequence, were integrated into the chicken ovalbumin gene locus using a CRISPR/Cas9 protocol. The knock-in hens produced a fully assembled humanized mAb in their eggs. The mAb expression level in the egg white was 1.4-1.9 mg/mL, as determined by ELISA. Furthermore, the antigen binding affinity of the anti-HER2 mAb obtained was estimated to be equal to that of the therapeutic anti-HER2 mAb (trastuzumab). In addition, antigen-specific binding by the egg white mAb was demonstrated by immunofluorescence against HER2-positive and -negative cells. These results indicate that the chicken bioreactor system can efficiently produce mAbs with antigen binding capacity and can serve as an alternative production system for commercial mAbs.
Subject(s)
Antibodies, Monoclonal/biosynthesis , CRISPR-Cas Systems , Chickens/genetics , Egg White/chemistry , Receptor, ErbB-2/antagonists & inhibitors , Animals , Animals, Genetically Modified , Antibodies, Monoclonal/isolation & purification , Bioreactors , Female , Gene Editing/methods , Humans , Plasmids/chemistry , Plasmids/metabolism , Receptor, ErbB-2/genetics , Receptor, ErbB-2/immunology , Trastuzumab/biosynthesis , Trastuzumab/isolation & purification , Zygote/chemistry , Zygote/metabolismABSTRACT
IgG is an indispensable biological experimental tool as well as a widely-used therapeutic protein. However, cell culture-based expression of monoclonal IgG is costly and time-consuming, making this process difficult to use for high-throughput screening in early-stage evaluation of biologics. With the goal of establishing a fast, simple, and robust high-throughput expression system for IgG, we implemented the synthesis of functional aglycosylated IgG by constructive approach based on a reconstituted prokaryotic cell-free protein synthesis system (PURE system). Optimization of the PURE system revealed that the following factors and reaction conditions were needed for IgG synthesis: (1) inclusion of the disulfide bond isomerase DsbC, (2) adjustment of the GSH/GSSG ratio, (3) inclusion of the molecular chaperone DnaK and its cofactors, and (4) use of an extended incubation time. Synthesis temperature and template DNA ratio (light chain-/heavy chain-encoding) also had been optimized for each IgG. Under optimal conditions, peak production of the anti-HER2 antibody trastuzumab reached 124 µg/mL. Furthermore, the active forms of other IgGs, including IgG1, IgG2, and IgG4 subclasses, also were synthesized. These results provide basic information for the development of novel high-throughput expression and functional screening systems for IgG, as well as useful information for understanding the IgG synthesis process.
Subject(s)
Immunoglobulin G/biosynthesis , Protein Engineering/methods , Cell Line , Cell-Free System , DNA-Binding Proteins/metabolism , Disulfides/chemistry , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Glutathione/metabolism , Humans , Membrane Proteins/genetics , Membrane Proteins/metabolism , Molecular Chaperones/metabolism , Oxidation-Reduction , Peptidylprolyl Isomerase/genetics , Peptidylprolyl Isomerase/metabolism , Protein Disulfide-Isomerases/metabolism , Receptor, ErbB-2/immunology , Solubility , Trastuzumab/biosynthesis , Trastuzumab/isolation & purification , Trastuzumab/pharmacologyABSTRACT
For pre-clinical evaluation of biotherapeutic candidates, protein production by transient gene expression (TGE) in Chinese Hamster Ovary (CHO) cells offers important advantages, including the capability of rapidly and cost-effectively generating recombinant proteins that are highly similar to those produced in stable CHO clones. We have established a novel CHO clone (CHO-3E7) expressing a form of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) with improved TGE productivity relative to parental CHO cells. Taking advantage of a new transfection-compatible media formulation that permits prolonged, high-density culture, we optimized transfection parameters (cell density, plasmid vector and polyethylenimine concentrations) and post-transfection culture conditions to establish a new, high-performing process for rapid protein production. The growth media is chemically defined, and a single hydrolysate feed is added post-transfection, followed by periodic glucose supplementation. This method gave significantly higher yields than our standard low-cell density, F17-based CHO-3E7 TGE method, averaging several hundred mg/l for a panel of recombinant proteins and antibodies. Purified antibodies produced using the two methods had distinct glycosylation profiles but showed identical target binding kinetics by SPR. Key advantages of this new protein production platform include the cost-effectiveness of the transfection reagent, the commercial availability of the culture media and the ability to perform high-cell-density transfection without media change.
Subject(s)
Epstein-Barr Virus Nuclear Antigens/genetics , Polyethyleneimine , Transfection/methods , Trastuzumab/biosynthesis , Animals , CHO Cells , Cell Count , Cricetulus , Gene ExpressionABSTRACT
The Brevibacillus expression system has been successfully employed for the efficient productions of a variety of recombinant proteins, including enzymes, cytokines, antigens and antibody fragments. Here, we succeeded in secretory expression of Trastuzumab Fab antibody fragments using B. choshinensis/BIC (Brevibacillus in vivocloning) expression system. In the fed-batch high-density cell culture, recombinant Trastuzumab Fab with amino-terminal His-tag (His-BcFab) was secreted at high level, 1.25â¯g/liter, and Fab without His-tag (BcFab) at â¼145â¯mg/L of culture supernatant. His-BcFab and BcFab were purified to homogeneity using combination of conventional column chromatographies with a yield of 10-13%. This BcFab preparation exhibited native structure and functions evaluated by enzyme-linked immunosorbent assay, surface plasmon resonance, circular dichroism measurements and size exclusion chromatography. To our knowledge, this is the highest production of Fab antibody fragments in gram-positive bacterial expression/secretion systems.
Subject(s)
Brevibacillus/metabolism , Gene Expression , Immunoglobulin Fab Fragments , Trastuzumab , Brevibacillus/genetics , Immunoglobulin Fab Fragments/biosynthesis , Immunoglobulin Fab Fragments/chemistry , Immunoglobulin Fab Fragments/genetics , Immunoglobulin Fab Fragments/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Trastuzumab/biosynthesis , Trastuzumab/chemistry , Trastuzumab/genetics , Trastuzumab/isolation & purificationABSTRACT
Chinese hamster ovary (CHO) cells are promising host engineering cells for industry manufacturing of therapeutic antibodies. However, cell death due to apoptosis remains a huge challenge to augment antibody production, and developing CHO cells with enhanced anti-apoptosis and proliferation ability is fundamental for cell line development and high-yielding bioprocesses. Deubiquitinase cylindromatosis (CYLD) has been proved to be a tumor suppressor by negatively regulating NF-κB and Wnt/ß-catenin signaling pathways. Its mutation or deletion is a common chromosome variation in several types of cancers. Here, we engineered CHO CYLD-/- cells by CRISPR-Cas9 editing technology. These cells displayed stronger cell proliferation and anti-apoptosis ability compared to parental cells. Three antibody expression plasmid kits were transiently transfected into these cells. Our data showed that inactivation of CYLD increased the highest titers of rituximab, Herceptin, and one bispecific antibody by 105, 63, and 228%, respectively. Reversely, overexpression of CYLD could promote cell apoptosis, whereas inhibiting cell proliferation and antibody production. Furthermore, inhibition of CYLD in CHO cells stably expressing an IgG antibody (CHO-IgG) achieved about 50% increase in product titer compared to parental cells. Meanwhile, inhibition of CYLD did not affect the quality of antibody. Thus, our data demonstrated that inactivation of CYLD could promote CHO cell proliferation, anti-apoptosis ability, and subsequent antibody production, suggesting that CYLD is a potential functional target for CHO cell engineering.
Subject(s)
Apoptosis/genetics , Cell Engineering , Cell Proliferation/genetics , Deubiquitinating Enzyme CYLD/genetics , Gene Silencing , Immunoglobulin G/biosynthesis , Animals , Antibodies, Bispecific/biosynthesis , CHO Cells , CRISPR-Cas Systems , Cricetinae , Cricetulus , Gene Deletion , Genes, Tumor Suppressor , Humans , Rituximab/biosynthesis , Trastuzumab/biosynthesisABSTRACT
Over the last years, a novel class of anti-cancer drugs named antibody-drug conjugates (ADCs) has been developed. Due to their limited off-target toxicity but highly potent cytotoxicity at tumor sites, ADCs have proven to be a good alternative to ordinary cancer treatment, such as chemotherapy or combination therapy. Numerous enhancements in antibody-drug engineering led to highly potent tumor targeting drugs with a wide therapeutic window. Two ADCs (Brentuximab vedotin and Trastuzumab emtansine) are already on the market and many others are in clinical trials. However, unstable linkers, low drug potency and unwanted bystander-effects are only some of the drawbacks of ADCs. Enzymes used in combination with prodrugs happen to be a promising alternative. The glyco-enzyme horseradish peroxidase (HRP) has proven to activate the hormone indole-3-acetic acid (IAA) to a highly potent cytotoxic drug. This combination of IAA and HRP has been investigated for the use in strategies such as gene-directed enzyme prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT). This article reviews the current state of research in ADC engineering and describes the potential major enhancements through use of glycoenzymes in combination with a prodrug.
Subject(s)
Antibodies, Monoclonal/biosynthesis , Antineoplastic Agents, Immunological/therapeutic use , Immunoconjugates/therapeutic use , Maytansine/analogs & derivatives , Molecular Targeted Therapy , Neoplasms/drug therapy , Trastuzumab/therapeutic use , Ado-Trastuzumab Emtansine , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents, Immunological/metabolism , Brentuximab Vedotin , Clinical Trials as Topic , Drug Design , Glycoconjugates/chemical synthesis , Glycoconjugates/therapeutic use , Horseradish Peroxidase/metabolism , Horseradish Peroxidase/therapeutic use , Humans , Immunoconjugates/chemistry , Indoleacetic Acids/metabolism , Maytansine/biosynthesis , Maytansine/therapeutic use , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/pathology , Prodrugs/chemical synthesis , Prodrugs/therapeutic use , Trastuzumab/biosynthesis , Tubulin Modulators/chemical synthesis , Tubulin Modulators/therapeutic useABSTRACT
Role of epigenetic regulation in the control of gene expression is well established. The impact of several epigenetic mechanisms, such as DNA methylation and histone acetylation, on recombinant protein production in mammalian cells has been investigated recently. Here we investigate the correlation between the selected epigenetic markers and five trastuzumab biosimilar-producing Chinese hamster ovary (CHO) cell lines in which the expression of trastuzumab is driven by human cytomegalovirus (HCMV) major immediate-early (MIE) promoter. We chose the producing clones in which transcription was the determinative step for the production of recombinant trastuzumab. We found that the abundance of trimethylation of histone 3 at lysine 4 (H3K4Me3) on the enhancer of HCMV MIE promoter correlated well with the relative titers of recombinant trastuzumab among the clones. Such close correlation was not observed between the recombinant protein and other epigenetic markers examined in our study. Our results demonstrate that the HCMV MIE enhancer-bound H3K4Me3 epigenetic marker may be used as the epigenetic indicator to predict the relative production of recombinant proteins between the producing CHO cell lines.
Subject(s)
Cytomegalovirus/genetics , Enhancer Elements, Genetic , Genes, Immediate-Early , Histones/metabolism , Lysine/metabolism , Promoter Regions, Genetic , Recombinant Proteins/metabolism , Trastuzumab/metabolism , Animals , CHO Cells , Cricetinae , Cricetulus , DNA Methylation , Gene Dosage , Humans , Methylation , RNA, Messenger/genetics , RNA, Messenger/metabolism , Trastuzumab/biosynthesis , Trastuzumab/geneticsABSTRACT
Cell-free protein synthesis (CFPS) systems allow for robust protein expression with easy manipulation of conditions to improve protein yield and folding. Recent technological developments have significantly increased the productivity and reduced the operating costs of CFPS systems, such that they can compete with conventional in vivo protein production platforms, while also offering new routes for the discovery and production of biotherapeutics. As cell-free systems have evolved, productivity increases have commonly been obtained by addition of components to previously designed reaction mixtures without careful re-examination of the essentiality of reagents from previous generations. Here we present a systematic sensitivity analysis of the components in a conventional Escherichia coli CFPS reaction mixture to evaluate their optimal concentrations for production of the immunoglobulin G trastuzumab. We identify eight changes to the system, which result in optimal expression of trastuzumab. We find that doubling the potassium glutamate concentration, while entirely eliminating pyruvate, coenzyme A, NAD, total tRNA, folinic acid, putrescine and ammonium glutamate, results in a highly productive cell-free system with a 95% reduction in reagent costs (excluding cell-extract, plasmid, and T7 RNA polymerase made in-house). A larger panel of other proteins was also tested and all show equivalent or improved yields with our simplified system. Furthermore, we demonstrate that all of the reagents for CFPS can be combined in a single freeze-thaw stable master mix to improve reliability and ease of use. These improvements are important for the application of the CFPS system in fields such as protein engineering, high-throughput screening, and biotherapeutics.
Subject(s)
Escherichia coli/metabolism , Immunoglobulin G/biosynthesis , Protein Biosynthesis , Protein Engineering/methods , Trastuzumab/biosynthesis , Coenzyme A/chemistry , DNA-Directed RNA Polymerases/chemistry , Escherichia coli/genetics , Gene Expression , Glutamic Acid/chemistry , Immunoglobulin G/genetics , Leucovorin/chemistry , NAD/chemistry , Polyamines/chemistry , Protein Folding , Putrescine/chemistry , Pyruvic Acid/chemistry , RNA, Transfer/chemistry , Reproducibility of Results , Trastuzumab/genetics , Viral Proteins/chemistryABSTRACT
Monovalent bispecific IgGs cater to a distinct set of mechanisms of action but are difficult to engineer and manufacture because of complexities associated with correct heavy and light chain pairing. We have created a novel design, "DuetMab," for efficient production of these molecules. The platform uses knobs-into-holes (KIH) technology for heterodimerization of 2 distinct heavy chains and increases the efficiency of cognate heavy and light chain pairing by replacing the native disulfide bond in one of the CH1-CL interfaces with an engineered disulfide bond. Using two pairs of antibodies, cetuximab (anti-EGFR) and trastuzumab (anti-HER2), and anti-CD40 and anti-CD70 antibodies, we demonstrate that DuetMab antibodies can be produced in a highly purified and active form, and show for the first time that monovalent bispecific IgGs can concurrently bind both antigens on the same cell. This last property compensates for the loss of avidity brought about by monovalency and improves selectivity toward the target cell.
Subject(s)
Antibodies, Bispecific , Antibody Affinity/genetics , Cetuximab , Immunoglobulin G , Trastuzumab , Antibodies, Bispecific/biosynthesis , Antibodies, Bispecific/chemistry , Antibodies, Bispecific/genetics , Cetuximab/biosynthesis , Cetuximab/chemistry , Cetuximab/genetics , HEK293 Cells , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/chemistry , Immunoglobulin G/genetics , Trastuzumab/biosynthesis , Trastuzumab/chemistry , Trastuzumab/geneticsABSTRACT
Cell culture processes that produce therapeutic antibodies with high productivity (titer) and low aggregate content reduce the risk of adverse effects and expense to patients. To elucidate the mechanism of aggregate formation, we compared trastuzumab samples produced from two contrasting cell lines: cell line A, which exhibits high titer and low aggregate content, and cell line B, which exhibits low titer and high aggregate content. Cell line B produced significantly fewer (approximately 1/3) antibodies compared with cell line A and contained higher (approximately 3-fold) percentages of aggregates. The aggregates of antibodies found in the protein A-purified samples of cell line B were associated mostly with noncovalent interactions. Cell line B exhibited a low content of monomers/dimers of light chains in the medium and within cells. Because light chains are essential for the correct folding of heavy chains and secretion of mature antibodies, the characteristics of cell line B may be attributed to low levels of light chain production. In addition, protein A-purified antibodies from cell line B (but not those from cell line A) contained fragments that are expected to expose the hydrophobic CH3 domain, which may serve as nuclei for aggregation.